EUVIMEDEUVIMED entdecken
Evaluationsstudie

Octreotide’s role in the management of post-esophagectomy chylothorax

Nathaniel Deboever, Hope Feldman, Michael Eisenberg, Mara B Antonoff, Reza J Mehran, Ravi Rajaram, David C Rice, Jack A Roth, Boris Sepesi, Stephen G Swisher, Ara A Vaporciyan, Garrett L Walsh und 1 weitere

Diseases of the Esophagus · 2024

DOI: 10.1093/dote/doae011 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Diseases of the Esophagus, 2024. Verfasst von Nathaniel Deboever und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Octreotide, Esophagectomy, Chylothorax, Length of Stay. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Mason Family Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of octreotide in managing intrathoracic chyle leak following esophagectomy has gained popularity in the adult population. While the benefits of octreotide have been confirmed in the pediatric population, there remains limited evidence to support its use in the adults post-esophagectomy. Thus, we performed a single-institution cohort study to characterize its efficacy. The study was performed using a prospective, single-center database, from which clinicopathologic characteristics were extracted of patients who had post-esophagectomy chyle leaks. Kaplan–Meier and multivariable Cox regression analyses were performed to investigate the effect of octreotide use on chest tube duration (CTD), hospital length of stay (LOS), and overall survival (OS). In our cohort, 74 patients met inclusion criteria, among whom 27 (36.5%) received octreotide. Kaplan–Meier revealed no significant effect of octreotide on CTD (P = 0.890), LOS (P = 0.740), or OS (P = 0.570). Multivariable Cox regression analyses further corroborated that octreotide had no effect on CTD (HR = 0.62, 95% confidence interval [CI]: 0.32–1.20, P = 0.155), LOS (HR = 0.64, CI: 0.34–1.21, P = 0.168), or OS (1.08, CI: 0.53–2.19, P = 0.833). Octreotide use in adult patients with chyle leak following esophagectomy lacks evidence of association with meaningful clinical outcomes. Level 1 evidence is needed prior to further consideration in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OctreotideEsophagectomyChylothoraxLength of StayPostoperative ComplicationsGastrointestinal AgentsHumansMaleFemaleMiddle AgedAgedKaplan-Meier EstimateProspective StudiesTreatment OutcomeChest TubesProportional Hazards ModelsAdultRetrospective Studies

Stichwörter der Autor:innen

adultchyle leakesophagectomyoctreotide

Substanzen

OctreotideGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Förderung

  • Mason Family Fund

Zitieren

APA

Deboever, N., Feldman, H., Eisenberg, M., Antonoff, M. B., Mehran, R. J., Rajaram, R., Rice, D. C., Roth, J. A., Sepesi, B., Swisher, S. G., Vaporciyan, A. A., Walsh, G. L., & Hofstetter, W. L. (2024). Octreotide’s role in the management of post-esophagectomy chylothorax. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae011

Vancouver

Deboever N, Feldman H, Eisenberg M, Antonoff MB, Mehran RJ, Rajaram R, et al. Octreotide’s role in the management of post-esophagectomy chylothorax. Diseases of the Esophagus. 2024. doi:10.1093/dote/doae011

BibTeX
@article{Deboever2024,
  author = {Deboever, Nathaniel and Feldman, Hope and Eisenberg, Michael and Antonoff, Mara B and Mehran, Reza J and Rajaram, Ravi and Rice, David C and Roth, Jack A and Sepesi, Boris and Swisher, Stephen G and Vaporciyan, Ara A and Walsh, Garrett L and Hofstetter, Wayne L},
  title = {Octreotide’s role in the management of post-esophagectomy chylothorax},
  journal = {Diseases of the Esophagus},
  year = {2024},
  doi = {10.1093/dote/doae011}
}
Kostenlos starten →